Utah Pilot Tests AI-Written Acne Prescriptions With Staged Doctor Review
Utah residents can now scan their faces in the Nolla Derm app for an AI assessment of acne and an AI-written prescription, Nolla Health announced on October 5, 2026. The Verge The service is starting as a pilot program limited to Utah.
The app is called Nolla Derm, and the company said AI-issued initial acne prescriptions, meaning first-time prescriptions rather than refills, began in Utah on October 5, 2026. Nolla Health It covers only Utah residents age 18 or older with mild-to-moderate acne, and it costs $4.99 per month. The Verge
Doctors check the work in stages, moving from review before prescribing to review after. Two physicians will approve each AI-generated prescription before it goes out for the first 100 patients. For patients up to 500, physicians will review the prescriptions after they are issued. After that, physicians will review a sample of at least 10% each month, plus every case involving escalation, when care needs to step up, or side effect. The Verge
The system grades acne severity from images, plus other skin traits such as oiliness. Los Angeles Times It can prescribe eight different skin treatments. If it cannot choose a treatment with enough confidence, it sends the user to a physician.
Nolla Health says it is the first in the United States to issue initial AI prescriptions, rather than renewals. Bloomberg described the Utah program as a first-of-its-kind pilot in which AI diagnoses and issues prescriptions. Bloomberg Utah began allowing AI systems to renew certain medications earlier in 2026. First-time prescribing faces different regulatory questions than refill automation.
Utah's AI prescription programs operate under the state's Office of Artificial Intelligence Policy. Bloomberg Law The state is working with healthcare AI companies to speed up prescription refills. One example already in use is Doctronic, an AI chatbot that lets Utah residents get refills online without an office visit.
Nolla's wider service predates this pilot. The company said in September 2025 that its AI-powered acne treatment was available in more than 40 U.S. states. It maintains a page titled "Nolla Derm AI Prescription: Now Piloting in Utah" at nollahealth.com/ai-prescriptions. Its corporate pages, which carry no date, state that every diagnosis and prescription is guided by a licensed U.S. medical provider and list Nolla Derm for acne, hyperpigmentation, rosacea, redness, melasma and wrinkles, alongside a Nolla Women service for birth control, UTI, yeast infection and BV, cycle concerns, menopause and sexual health, and a Health Assistant service for symptoms, next steps, prescriptions and on-demand care.
The broader context here is staged testing for clinical independence. Early review before prescribing builds a checked set of cases. Later review after prescribing tests whether accuracy holds as volume rises and whether uncertain cases are correctly sent to doctors. Sampling 10% plus full review of worsening cases and side effects borrows a standard audit habit from software reliability. In my view, that structure fits this risk level. Mild-to-moderate acne in adults, limited to eight options with a defined handoff when confidence is low, keeps potential harm contained while producing the follow-up data regulators will need.
Looking at what this means for technologists, the hard part is not the face scan. It is confidence calibration, meaning an accurate sense of uncertainty, plus complete audit logs and making sure no uncertain case slips through. Worth flagging, a system that knows when to say it is unsure and routes to a physician will be safer than a slightly more accurate grader with poor abstention. If Utah's Office can compare sampled outcomes, refills against first-time prescribing, and referral rates across vendors, other states will have a template to copy. That could widen access to routine skin care without making unsupervised prescribing normal for higher-risk conditions.
